Document Detail

Sideroblastic anaemia and leukaemia in multiple myeloma.
MedLine Citation:
PMID:  105698     Owner:  NLM     Status:  MEDLINE    
Two patients with IgA myeloma and one patient with kappa light chain disease developed sideroblastic anaemia from two to four years after the initial diagnosis. All had previously received radiotherapy and chemotherapy (melphalan and prednisone). In two patients the myeloma was quiescent when the sideroblastic change occurred. Leukaemia occurred in two patients two and seven months respectively after the diagnosis of sideroblastic anaemia was made. In one of them, the myeloma became active again at the same time. The development of sideroblastic anaemia may be a pre-leukaemic event and may be recognised by the appearance of a dimorphic blood film.
K P Phadke; Y L Kwan; S G Young
Related Documents :
11288758 - Unanticipated favorable effects of correcting iron deficiency in chronic hemodialysis p...
660358 - Anemia in patients with juvenile rheumatoid arthritis.
949188 - Primary hyperparathyroidism and anemia.
15824508 - Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients...
23354188 - Ultrasound predictors of compensated liver cirrhosis in hemodialysis patients with hepa...
872318 - The determinants of atrioventricular nodal re-entrance with premature atrial stimulatio...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Australian and New Zealand journal of medicine     Volume:  8     ISSN:  0004-8291     ISO Abbreviation:  Aust N Z J Med     Publication Date:  1978 Oct 
Date Detail:
Created Date:  1979-04-26     Completed Date:  1979-04-26     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  1264322     Medline TA:  Aust N Z J Med     Country:  AUSTRALIA    
Other Details:
Languages:  eng     Pagination:  539-43     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Sideroblastic / etiology*
Immunoglobulin A
Immunoglobulin kappa-Chains
Leukemia / etiology*
Melphalan / adverse effects,  therapeutic use
Middle Aged
Multiple Myeloma / complications*,  immunology,  therapy
Prednisone / adverse effects,  therapeutic use
Reg. No./Substance:
0/Immunoglobulin A; 0/Immunoglobulin kappa-Chains; 148-82-3/Melphalan; 53-03-2/Prednisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A longitudinal study of the effectiveness of self applied 10 per cent stannous fluoride paste for se...
Next Document:  Brucella cultures typed by the Who Brucellosis Centre at the Commonwealth Serum Laboratories, Melbou...